Navigation Links
Cancer immunotherapy shows long-term promise in lung cancer
Date:4/24/2008

New, long-term results from a clinical trial presented today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association of the Study of Lung Cancer (IASLC) show that MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic), an immune-boosting treatment for lung cancer patients, reduces the risk of relapse after surgery -- to the same extent as chemotherapy but without the side-effects of chemotherapy.

Prof. Johan Vansteenkiste from University Hospital Gasthuisberg in Belgium described the results after 44-months follow-up from a double-blind, placebo-controlled trial in 182 patients with non-small-cell lung cancer -- the most common form of the disease.

After complete surgical resection of the tumor, patients were randomly assigned to receive either placebo injections or injections of MAGE-A3 ASCI administered over 27 months (five given at three-week intervals followed by eight given once every three months). MAGE-A3 is a tumor-specific antigen, expressed in 35-50% of non-small-cell lung cancer, but not on normal cells.

"The aim is to help the body immune system to recognize the MAGE-A3 antigen and therefore eliminate the cancer cells that express MAGE-A3," explains Prof. Vansteenkiste. "In other words, it is a kind of treatment method that makes the body immune system specifically attack the lung cancer cells."

After 44 months, 69 of 182 patients had experienced a recurrence of their cancer, including 57 deaths. Those given the MAGE-A3 injections had longer on average before their cancer recurred, were less likely to have any recurrence, and were less likely to die.

"Surgical resection is the standard treatment for patients with early stage lung cancer, but after complete resection about 50% will relapse and die from their cancer," says Prof. Vansteenkiste. "Postoperative chemotherapy is able to improve cure rates, but is someti
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers reveal structure of protein that repairs damage to cancer cells
2. Pregnancy is possible after cancer treatment
3. Effective cancer immune therapy through order in the blood vessels
4. Fox Chase researchers discover a method for clamping down on a cancer-promoting enzyme
5. Breast cancers behave differently before and after the age of 70
6. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
7. Ovarian cancer stem cells identified, characterized
8. Inherited cancer mutation is widespread in America
9. New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
10. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
11. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small Cap ... report showed that planet-wide, transactions at merchants on the leading ... total number of credit, debit, and prepaid cards reached 6.54 ... victims of fraudulent card usage in 2012, and credit and ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... 2009 / b3c newswire / - DuoCort ... rare and life threatening disease adrenal insufficiency. The release ... hydrocortisone dosing closely resembles the physiological secretion pattern. The ... Endocrinology, a leading scientific journal for endocrinology. ...
... for the organism, and this is true even for the ... of present marine mammals initiated their return to the oceans, ... Dr. Michael Berenbrink and his colleagues at Liverpool University have ... to the muscles during locomotion, has been modified in seals ...
... pregnancy or in previous pregnancies can predict the,likelihood ... according to research carried out by an,international group ... to predict more easily which women might need ... enabling new research to improve clinical management of ...
Cached Biology News:DuoCort: New chronotherapy for adrenal insufficiency 2DuoCort: New chronotherapy for adrenal insufficiency 3Natural-born divers and the molecular traces of evolution 2Complications early in pregnancy or in previous pregnancies adversely affect existing or subsequent pregnancies 2Complications early in pregnancy or in previous pregnancies adversely affect existing or subsequent pregnancies 3
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
(Date:1/22/2015)... 2015  Varian Medical Systems (NYSE: VAR ), world ... its commitment to sustainability with inclusion on a prestigious list ... ranked healthcare equipment company among the Corporate Knights Global 100 ... Forum at Davos, Switzerland . ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... , , FRAMINGHAM, ... HTWR ) (ASX: HIN) today confirmed that trading ... Exchange ("ASX") was temporarily suspended for the reasons stated below. ... NASDAQ is also temporarily suspended. Based on discussions with ...
... , ANNAPOLIS, Md., Sept. 1 PharmAthene, Inc. ... medical countermeasures against biological and chemical threats, announced today that ... Investment Conference 2009. The Company is scheduled to present ... the Hubbard Salon (5th Floor) at the New York Palace ...
... , , DALLAS, Sept. 1 ... (OTC Bulletin Board : ACCP) announced today that ... be held September 9-11, 2009 at the New York Palace Hotel in New ... to speak on Friday, September 11, 2009 at 10:50 am EDT in the ...
Cached Biology Technology:HeartWare International, Inc. Temporary Suspension of Trading 2HeartWare International, Inc. Temporary Suspension of Trading 3Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference 2Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference 3
Mouse monoclonal antibody to FMN2 - formin 2...
...
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
... (KLF15) KLF15 is a Cys2-His2 zinc ... in the liver, kidneys, heart, and skeletal ... Polyclonal antibody produced in rabbits immunized with ... of human KLF15 with an internal ID ...
Biology Products: